Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Hyftor Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Hyftor Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs commercial coverage for Hyftor 0.2% sirolimus gel for patients with tuberous sclerosis complex and facial angiofibromas. It establishes initial authorization, renewal, specialist, contraindication, and quantity-limit requirements for the Boeing formulary.

    Policy Summary
    PayerPrime Therapeutics
    PolicyHyftor Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming TSC, at least three qualifying facial angiofibromas, specialist involvement or consultation, and no FDA-labeled contraindication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    0.2%Hyftor strength
    12 monthsApproval duration
    3+Required facial angiofibromas
    84 tubesQuantity limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 major or 1+2 minor
    TSC diagnostic pathway

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • ONE of the following confirms tuberous sclerosis complex (TSC):

      • The patient has two major features of TSC clinical diagnostic criteria:

        • At least TWO major features

          • Hypomelanotic macules (at least 3, each at least 5 mm in diameter)
          • Angiofibromas (at least 3) or fibrous cephalic plaque
          • Ungual fibromas (at least 2)
          • Shagreen patch
          • Multiple retinal hamartomas
          • Multiple cortical tubers and/or radial migration lines
          • Subependymal nodules (at least 2)
          • Subependymal giant cell astrocytoma
          • Cardiac rhabdomyoma
          • Lymphangioleiomyomatosis (LAM)
          • Angiomyolipomas (at least 2)
      • The patient has one major feature and two minor features of TSC clinical diagnostic criteria:

        • At least ONE major feature

          • Hypomelanotic macules (at least 3, each at least 5 mm in diameter)
          • Angiofibromas (at least 3) or fibrous cephalic plaque
          • Ungual fibromas (at least 2)
          • Shagreen patch
          • Multiple retinal hamartomas
          • Multiple cortical tubers and/or radial migration lines
      • The patient has a pathogenic variant in the TSC1 gene or TSC2 gene confirmed by genetic testing
    • The patient has three or more facial angiofibromas that are at least 2 mm in diameter, with redness in each
    • If the patient has an FDA-labeled indication, ONE of the following applies:

      • The patient's age is within FDA labeling for the requested indication for the requested agent
      • There is support for using the requested agent for the patient's age for the requested indication
    • The prescriber is a specialist in the area of the patient's diagnosis (for example, a dermatologist or geneticist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis
    • The patient does NOT have any FDA-labeled contraindications to the requested agent

    Continuation or Renewal Therapy

    Covered when ALL of the following renewal criteria are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process

      Patients not previously approved for the requested agent require initial evaluation review.

    • The patient has had clinical benefit with the requested agent
    • The prescriber is a specialist in the area of the patient's diagnosis (for example, a dermatologist or geneticist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis
    • The patient does NOT have any FDA-labeled contraindications to the requested agent

    Quantity-Limit Criteria

    The requested quantity (dose) is covered when ONE of the following criteria is met:

    ONE of the following:

    • The requested quantity (dose) does NOT exceed the program quantity limit
    • The requested quantity (dose) exceeds the program quantity limit, and BOTH of the following apply:

      • The requested agent does NOT have a maximum FDA-labeled dose for the requested indication
      • There is support for therapy with a higher dose for the requested indication
    • The requested quantity (dose) exceeds the program quantity limit, and BOTH of the following apply:

      • The requested quantity (dose) does NOT exceed the maximum FDA-labeled dose for the requested indication

    FDA-labeled contraindications exclude approval. The requested agent is not approved when the patient has any contraindication identified in the agent's FDA-approved labeling.

    Clinical Coding and Qualifying Features

    Facial angiofibroma requirements
    Minimum lesion count3 or more facial angiofibromas
    Lesion sizeEach lesion must be at least 2 mm in diameter
    Lesion appearanceRedness must be present in each lesion
    Tuberous sclerosis complex clinical criteria
    Two-major-feature pathwayTwo major features of tuberous sclerosis complex
    Combined-feature pathwayOne major feature plus two minor features of tuberous sclerosis complex
    Feature categories

    Provider Actions and Authorization Guidance

    Prior Authorization

    Initial Prior Authorization Required

    Submit an initial prior authorization request for Hyftor with documentation addressing every clinical approval criterion. Initial approval is limited to 12 months; if a quantity limit applies, submit the separate quantity-limit support described below.

    • Document the TSC diagnosis, qualifying facial angiofibromas, age/indication support, specialist involvement, and absence of FDA-labeled contraindications.
    Prior Authorization

    Renewal Prior Authorization

    Document renewal eligibility by showing that the patient was previously approved for the requested agent through the plan’s prior authorization process and has experienced clinical benefit. Renewal approval is limited to 12 months.

    • Patients without prior plan approval require initial-evaluation review.
    • Document continued specialist prescribing or specialist consultation and the absence of FDA-labeled contraindications.

    Policy Background

    Tuberous sclerosis complex (TSC) is a genetic disorder identified through characteristic major and minor clinical features or through genetic confirmation of a pathogenic variant in the TSC1 or TSC2 gene. For this policy, the treated manifestation is facial angiofibromas associated with TSC, requiring at least three lesions, each measuring at least 2 mm in diameter and showing redness.

    Definitions

    Tuberous sclerosis complex definition
    Clinical diagnosisTuberous sclerosis complex is confirmed by two major features
    Combined clinical diagnosisTuberous sclerosis complex is also confirmed by one major feature plus two minor features
    Genetic diagnosisA pathogenic variant in the TSC1 gene or TSC2 gene confirmed by genetic testing confirms tuberous sclerosis complex
    Qualifying facial angiofibromas
    Required numberThree or more facial angiofibromas
    Required sizeEach facial angiofibroma must be at least 2 mm in diameter
    Required appearance

    Hyftor Initial Approval

    Hyftor Initial Approval

    Initial therapy is approved when ALL policy criteria are met.

    Hyftor initial approval

    • Confirmed tuberous sclerosis complex

      • Clinical diagnostic criteria: The patient has two major features OR one major feature and two minor features of tuberous sclerosis complex clinical diagnostic criteria.2 major features OR 1 major feature plus 2 minor features
      • Genetic confirmation: The patient has a pathogenic variant in the TSC1 gene or TSC2 gene confirmed by genetic testing.Pathogenic TSC1 or TSC2 variant

    Hyftor Renewal

    Hyftor Renewal

    Renewal is approved when ALL of the following are met.

    Hyftor renewal

    • Previous plan approval: The patient was previously approved for Hyftor through the plan's prior authorization process.
    • Clinical benefit: The patient has had clinical benefit with Hyftor.
    • Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, such as a dermatologist or geneticist, or the prescriber has consulted with such a specialist.
    • No FDA-labeled contraindication:

    Hyftor Quantity Limit

    Quantity limit
    AgentHyftor (sirolimus gel)
    Strength0.2%
    Quantity limit84 tubes
    Policy Summary
    PayerPrime Therapeutics
    PolicyHyftor Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming TSC, at least three qualifying facial angiofibromas, specialist involvement or consultation, and no FDA-labeled contraindication.
    SourceLink
    On This Page
    Coverage CriteriaClinical Coding and Qualifying FeaturesProvider Actions and Authorization GuidancePolicy BackgroundDefinitionsHyftor Initial ApprovalHyftor RenewalHyftor Quantity Limit
    Subependymal nodules (at least 2)
  1. Subependymal giant cell astrocytoma
  2. Cardiac rhabdomyoma
  3. Lymphangioleiomyomatosis (LAM)
  4. Angiomyolipomas (at least 2)
  5. At least TWO minor features

    • Confetti skin lesions
    • Dental enamel pits (at least 3)
    • Intraoral fibromas (at least 2)
    • Retinal achromic patch
    • Multiple renal cysts
    • Nonrenal hamartomas
    • Sclerotic bone lesions
  6. There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit
  7. The requested quantity (dose) exceeds the program quantity limit, and BOTH of the following apply:

    • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication
    • There is support for therapy with a higher dose for the requested indication
  8. Major and minor clinical features are those listed in the policy diagnostic criteria
    Documentation Required

    TSC Diagnosis and Lesion Documentation

    Support the TSC diagnosis with either the defined clinical diagnostic criteria or genetic confirmation, and document the required facial lesions.

    • Clinical diagnosis: two major features or one major and two minor features of TSC.
    • Major features include hypomelanotic macules (≥3, each ≥5 mm), angiofibromas (≥3) or fibrous cephalic plaque, ungual fibromas (≥2), shagreen patch, multiple retinal hamartomas, multiple cortical tubers and/or radial migration lines, subependymal nodules (≥2), or subependymal giant cell astrocytoma.
    • Major features also include renal angiomyolipomas (≥2); a combination of lymphangioleiomyomatosis and angiomyolipomas without other features does not establish a definite diagnosis.
    • Minor features include confetti skin lesions, dental enamel pits (≥3), intraoral fibromas (≥2), retinal achromic patch, multiple renal cysts, nonrenal hamartomas, or sclerotic bone lesions.
    • Alternatively, document a pathogenic TSC1 or TSC2 variant confirmed by genetic testing.
    • Document three or more facial angiofibromas, each at least 2 mm in diameter, with redness in each lesion.
    Documentation Required

    Age, Specialist, and Safety Documentation

    Provide patient and prescriber documentation showing that the requested use is clinically appropriate and safe.

    • If an FDA-labeled indication applies, document that the patient’s age is within FDA labeling for the requested indication, or provide support for use in the patient’s age group.
    • Document that the prescriber is a specialist in the area of the diagnosis, such as a dermatologist or geneticist, or has consulted with an appropriate specialist.
    • Document that the patient has no FDA-labeled contraindications to the requested agent.
    Documentation Required

    Renewal Response Documentation

    For a renewal response, demonstrate both prior plan approval and ongoing benefit from the requested agent. The response must also address the continuing specialist and safety requirements.

    • Confirm previous approval through the plan’s prior authorization process.
    • Document clinical benefit with the requested agent.
    • Document specialist prescribing or consultation and no FDA-labeled contraindications.
    Billing Rule

    Quantity-Limit Exception Documentation

    When the requested dose or quantity exceeds the program quantity limit, submit documentation supporting the applicable exception pathway.

    • If there is no maximum FDA-labeled dose for the indication, document support for therapy with a higher dose.
    • If the quantity does not exceed the maximum FDA-labeled dose, document why the requested quantity cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    • If the requested quantity exceeds the maximum FDA-labeled dose, document support for therapy with the higher dose.
    Denial Risk

    Failure to Meet Initial Approval Criteria

    Initial approval may be denied when the request does not satisfy every required clinical criterion.

    • TSC is not confirmed by the required clinical features or pathogenic TSC1/TSC2 genetic finding.
    • The patient does not have at least three facial angiofibromas measuring at least 2 mm with redness in each lesion.
    • The requested age is outside FDA labeling without supporting evidence for the requested indication and age.
    • The prescriber is not an appropriate specialist and has not documented specialist consultation.
    • The patient has an FDA-labeled contraindication to the requested agent.
    Denial Risk

    Renewal Requirements Not Met

    Renewal may be denied when the patient does not meet all renewal requirements.

    • The patient was not previously approved for the requested agent through the plan’s prior authorization process; initial-evaluation review is required instead.
    • The patient has not demonstrated clinical benefit with the requested agent.
    • The prescriber is not a specialist and has not consulted with an appropriate specialist.
    • The patient has an FDA-labeled contraindication to the requested agent.
    Denial Risk

    Quantity Exceeds Program Limit

    A quantity exceeding the program limit requires documented support for an applicable exception. Without that support, the requested higher dose or quantity may be denied.

    • For a requested quantity above the program limit, document the applicable higher-dose or quantity rationale described in the quantity-limit criteria.
    • Support must address the absence or presence of a maximum FDA-labeled dose, the medical need for a higher dose, or why a lower quantity of a higher strength cannot achieve the requested dose within the program limit.
    Each lesion must show redness
    Qualifying facial angiofibromas: The patient has three or more facial angiofibromas that are at least 2 mm in diameter, with redness in each.>= 3 lesions; each >= 2 mm with redness
  9. FDA-labeled age support when applicable

    • The patient's age is within FDA labeling for the requested indication and requested agent.
    • There is support for using Hyftor for the patient's age and requested indication.
  10. Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, such as a dermatologist or geneticist, or the prescriber has consulted with such a specialist.
  11. No FDA-labeled contraindication: The patient does not have any FDA-labeled contraindications to Hyftor or the requested agent.
  12. The patient does not have any FDA-labeled contraindications to Hyftor or the requested agent.